Loading...
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of light
Ackermann, Christoph J Reck, M Paz-Ares, L Barlesi, F Califano, Raffaele
Ackermann, Christoph J
Reck, M
Paz-Ares, L
Barlesi, F
Califano, Raffaele
Citations
Altmetric:
Abstract
The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations.
Description
Date
2019
Publisher
Collections
Keywords
Type
Article
Citation
Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R. First-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of light. Lung Cancer. 2019;134:245-53.